
|Videos|December 13, 2020
Analysis of investigational ophthalmic solution for treating presbyopia-related symptoms
Author(s)Alex Delaney-Gesing , David Hutton
Michael R. Robinson, MD, Allergan, discusses the results from a study analyzing an investigational ophthalmic solution for treatment of symptoms associated with presbyopia presented during the virtual AAO 2020 meeting.
Advertisement
Michael R. Robinson, MD, vice president, Global Therapeutic Area Head, Ophthalmology at Allergan, an AbbVie company, discusses the results from a presentation titled, "Two Phase b Study Results for the Development of a Proprietary Formulation for the Treatment of Presbyopia," presented during the virtual AAO 2020 meeting.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
STAAR Surgical terminates proposed acquisition by Alcon
2
FDA grants Breakthrough Therapy Designation to Oculis’ privosegtor for optic neuritis
3
Rates of retinal layer thinning predict visual field progression in glaucoma
4
International meta-analysis highlights elevated ocular risk in Clade I Monkeypox
5











































